No Data
No Data
Top Executive Makes Bold Move With Major Stock Purchase in Zevra Therapeutics!
New Analyst Forecast: $ZVRA Given $22.0 Price Target
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Optimistic Buy Rating for Zevra Therapeutics Driven by Miplyffa Launch and Strategic Financial Moves
Zevra Therapeutics Is Maintained at Buy by Guggenheim